The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...

Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, and welcome to the BioXcel Therapeutics Third ...

Vincent O'Neill; Executive Vice President, Chief of Product Development and Medical Officer; BioXcel Therapeutics Inc Alec Stranahan; Analyst; BofA Securities, Inc.

Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...

Nine-month Results Remain On Track for Net ProfitAd Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 11, 2024-Addex ...